StockData
Cytokinetics Inc logo

Cytokinetics Inc (CYTK) company profile

CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30
$51.65−1.52 (-2.86%)

Close on Nov 17, 2026Market cap $7.18BP/E –Yield –

About Cytokinetics

Pharmaceutical Preparations, SIC 2834

Cytokinetics is a biopharmaceutical company dedicated to discovering, developing, and commercializing small-molecule therapeutics targeting muscle biology to treat severe cardiovascular and neuromuscular diseases. Its core research centers on the cytoskeleton and sarcomere mechanics, organized into cardiac and skeletal muscle contractility programs. The company's first commercial product is MYQORZO (aficamten), an oral cardiac myosin inhibitor approved for adults with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics also advances a pipeline of clinical candidates, including omecamtiv mecarbil, ulacamten, and CK-089. Its commercial focus directs therapies toward specialized customer segments, primarily cardiologists, academic centers of excellence, and focused healthcare providers.

The company maintains commercial sales and distribution operations in the United States and collaborates with licensing partners, including Sanofi in China and Bayer in Japan, to reach patient populations across North America, Europe, and Asia. Regulatory approvals for MYQORZO cover the United States, the European Union, and China, with planned commercial rollouts extending into Germany and additional major European nations. The text does not disclose the location of the corporate headquarters.

Summary of the business section of Cytokinetics's latest annual report, written by StockData.

Company profile

Company

Legal name
Cytokinetics Inc
Founded
1997
Headquarters
South San Francisco, CA
Address
350 Oyster Point Boulevard, . 94080
Phone
(650) 624-3000
Employees
673, Dec 31, 2025
Industry
Pharmaceutical Preparations
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Jose, California

Stock & identifiers

Ticker
CYTK
Exchange
Nasdaq
IPO date
Apr 30, 2004
Shares outstanding
139M, Aug 4, 2026
Public float
$2.50B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
1-for-6 reverse, Jun 25, 2013
SEC CIK
1061983
CUSIP
23282W605
ISIN
US23282W6057
FIGI
BBG000F0R4N9
Share class FIGI
BBG001SGMVF2
LEI
549300BE5DY1HW7IHA64
EIN
94-3291317

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Robert I. BlumPresident & CEO, Director282,710
Fady Ibraham MalikEVP Research & Development153,902
Andrew CallosEVP, Chief Commercial Officer58,555
Sung LeeEVP, Chief Financial Officer63,221
Jeffrey HessekielChief Legal & Admin Officer107,943
Robert WongVP, Chief Accounting Officer17,889
B. Lynne ParshallDirector5,784
Robert Arthur HarringtonDirector22,127
James M. DalyDirector3,585
Edward M. Kaye MDDirector10,629
Nancy WysenskiDirector34,089
John T. HendersonDirector78,795
Wendell WierengaDirector35,660
Robert E. LandryDirector8,184
Muna BhanjiDirector26,361
Wendall WierengaDirector32,345

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$11.88M$15.83M$4.53M$306$120
FY2024$14.36M-$1.68M$4.56M$443$114
FY2023$8.74M$20.68M$2.91M$787$115
FY2022$8.54M$8.69M$2.33M$432$111
FY2021$6.41M$19.86M$2.75M$430$125
FY2020$5.13M$10.99M$1.80M$196$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Robert I. Blum
Principal Executive Officer
$853.07K–$5.15M$5.10M$772.72K$9.74K$11.88M-17%
Andrew M. Callos
Executive Vice President, Chief Commercial Officer
$581.68K–$1.45M$1.43M$302.96K$18.25K$3.79M-14%
Jeffrey Hessekiel
Executive Vice President, Chief Legal & Administrative Officer
$85.25K$200.00K$5.80M––$954$6.09M–
Sung H. Lee
Principal Financial Officer
$572.92K–$1.45M$1.43M$295.61K$17.52K$3.77M-34%
Fady I. Malik
Executive Vice President, Research and Development
$629.78K–$1.75M$1.73M$335.14K$20.52K$4.47M-17%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 673 employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?